IRadimed Corp. (IRMD)

Over the past six months, IRadimed Corp. has experienced several events impacting its stock price. IRadimed reported its 17th consecutive quarter of record revenue in Q3 2025, leading to an increase in stock price and raised full-year guidance. The FDA granted clearance for IRadimed's next-generation MRidium® 3870 IV Infusion Pump System in May 2025, expected to drive significant growth in 2026. IRadimed was named to TIME's list of America's Growth Leaders for 2026, highlighting its financial strength and stock performance. A director sold 3,000 shares of IRadimed stock, but the overall stock score remained "Outperform". The company declared a regular quarterly cash dividend of $0.17 per share for Q4 2025.

While specific seasonal fluctuations are not detailed, IRadimed Corp. has demonstrated consistent revenue growth, reporting 17 consecutive quarters of record revenue. Demand is influenced by technological innovation, regulatory approvals, and the market for MRI-compatible devices. The company anticipates continued growth driven by a new IV pump replacement cycle and increasing demand for portable MRI solutions.

IRadimed Corporation is a medical device company specializing in MRI-compatible products, including IV infusion pump systems and patient vital signs monitoring systems. These devices are designed with non-magnetic components for safe operation during MRI procedures. The company also provides related accessories, disposables, and services.

IRadimed Corp. is headquartered in Winter Springs, Florida, with a significant presence in the United States, accounting for over 80% of its total revenue. The company also has an international market presence, selling its MRI products globally. Expansion efforts include gaining approval to sell products in Japan in 2017, with Europe and Japan rollouts for the new 3870 pump planned for 2027, pending regulatory clearances targeted for late 2026.

IRadimed Corp. has maintained a positive brand reputation, marked by industry recognition. The company was named on Forbes' list of America's Most Successful Small-Cap Companies for 2024 and selected for TIME's list of America's Growth Leaders for 2026. The company's focus on patient safety and its position as the only known provider of a non-magnetic IV infusion pump system specifically designed for MRI procedures contribute to its strong standing.

IRadimed Corp. is owned by a mix of institutional investors, insiders, and retail investors. Institutional investors hold 53.33% of shares, insiders hold 36.81%, and retail investors hold 9.86%. BlackRock, Inc. is the largest institutional shareholder. The company's CEO, Roger Susi, is a significant individual shareholder.